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Abstract
Background: Chronic kidney disease (CKD) is a frequent, under-recognized condition and a risk factor for renal failure and
cardiovascular disease. Increasing evidence connects non-alcoholic fatty liver disease (NAFLD) to CKD. We conducted a
meta-analysis to determine whether the presence and severity of NAFLD are associated with the presence and severity of
CKD.
Methods and Findings: English and non-English articles from international online databases from 1980 through January 31,
2014 were searched. Observational studies assessing NAFLD by histology, imaging, or biochemistry and defining CKD as
either estimated glomerular filtration rate (eGFR) ,60 ml/min/1.73 m2 or proteinuria were included. Two reviewers
extracted studies independently and in duplicate. Individual participant data (IPD) were solicited from all selected studies.
Studies providing IPD were combined with studies providing only aggregate data with the two-stage method. Main
outcomes were pooled using random-effects models. Sensitivity and subgroup analyses were used to explore sources of
heterogeneity and the effect of potential confounders. The influences of age, whole-body/abdominal obesity, homeostasis
model of insulin resistance (HOMA-IR), and duration of follow-up on effect estimates were assessed by meta-regression.
Thirty-three studies (63,902 participants, 16 population-based and 17 hospital-based, 20 cross-sectional, and 13
longitudinal) were included. For 20 studies (61% of included studies, 11 cross-sectional and nine longitudinal, 29,282
participants), we obtained IPD. NAFLD was associated with an increased risk of prevalent (odds ratio [OR] 2.12, 95% CI 1.69–
2.66) and incident (hazard ratio [HR] 1.79, 95% CI 1.65–1.95) CKD. Non-alcoholic steatohepatitis (NASH) was associated with
a higher prevalence (OR 2.53, 95% CI 1.58–4.05) and incidence (HR 2.12, 95% CI 1.42–3.17) of CKD than simple steatosis.
Advanced fibrosis was associated with a higher prevalence (OR 5.20, 95% CI 3.14–8.61) and incidence (HR 3.29, 95% CI 2.30–
4.71) of CKD than non-advanced fibrosis. In all analyses, the magnitude and direction of effects remained unaffected by
diabetes status, after adjustment for other risk factors, and in other subgroup and meta-regression analyses. In cross-
sectional and longitudinal studies, the severity of NAFLD was positively associated with CKD stages. Limitations of analysis
are the relatively small size of studies utilizing liver histology and the suboptimal sensitivity of ultrasound and biochemistry
for NAFLD detection in population-based studies.
Conclusion: The presence and severity of NAFLD are associated with an increased risk and severity of CKD.
Please see later in the article for the Editors’ Summary.
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Introduction
Chronic kidney disease (CKD) affects 4%–13% of the
Western adult population and over 25% of individuals older
than 65 years [1]. CKD prevalence is continuously rising in
concert with the rising epidemic of its risk factors including
ageing, diabetes, obesity, metabolic syndrome, smoking, and
hypertension [2–4]. In the United States, over 400,000 people
currently receive some form of renal replacement therapy, and
this number is expected to reach 2.2 million by 2030 [2]. Beside
being a risk factor for end-stage renal disease (ESRD), CKD is
an important cardiovascular disease (CVD) risk factor, and most
patients with CKD die from CVD before any renal replacement
therapy is initiated [5].
Early recognition and treatment of CKD aimed at reducing
renal disease progression and CVD complications may limit its
health-related burden [4]. In particular, patients with stage 3
CKD benefit the most from early referral strategies [6]. Despite
these premises, CKD often goes unrecognized: in the Third
National Health and Nutrition Survey (NHANES III), among
all individuals with stage 3 CKD, the awareness was only 8.2%
[7].
The high morbidity, mortality, and health care costs associated
with CKD have led investigators to seek novel modifiable risk
factors. Non-alcoholic fatty liver disease (NAFLD), the hepatic
manifestation of the metabolic syndrome, affects 30% of the
general adult population and up to 60%–70% of diabetic and
obese patients [8]. NAFLD encompasses a histological spectrum
ranging from simple steatosis to non-alcoholic steatohepatitis
(NASH), the latter with or without advanced fibrosis. NAFLD
confers an increased risk of cirrhosis, largely limited to NASH, and
of CVD, independently of metabolic syndrome and traditional risk
factors and through mechanisms which remain unclear [9].
Growing experimental and epidemiological evidence suggests that
NAFLD and CKD share common pathogenic mechanisms and
interactions [10]. However, evidence of a link between NAFLD
and CKD is uncertain due to the small study populations and the
borderline associations between NAFLD and traditional risk
factors for CKD in the published literature. A meta-analysis on
the association of NAFLD and CKD has not been conducted to
date. We therefore analysed the evidence regarding two research
questions: (1) Does NAFLD affect the risk of CKD independent of
major confounders? (2) Is NAFLD severity associated with the
severity of CKD?
Methods
Data Sources and Searches
We searched English and non-English language publications
on MEDLINE, Ovid MEDLINE In-Process, EMBASE, ISI
Web of Science, and Cochrane Library, and abstracts from the
annual American Association for the Study of Liver Disease
(AASLD), the American Gastroenterological Association (AGA),
the European Association for the Study of the Liver (EASL), the
Digestive Disease Week (DDW), and the American Society of
Nephrology (ASN) Kidney Week meetings from 1980 through
January 31, 2014. Search terms were: chronic kidney disease
OR CKD OR kidney function OR kidney failure OR renal
disease OR renal insufficiency OR renal failure OR glomerular
filtration rate (GFR) OR estimated glomerular filtration rate
(eGFR) OR creatinine OR albuminuria OR microalbuminuria
OR macroalbuminuria OR proteinuria OR kidney injury AND
NASH OR NAFLD OR non-alcoholic steatohepatitis OR non-
alcoholic fatty liver disease OR fatty liver OR liver fat OR
steatosis OR liver enzymes OR transaminase OR ALT OR AST
OR GGT OR severity of liver disease OR fibrosis. A full list of
the search strategies in different databases is reported in Text
S2.
Study Selection
Inclusion criteria. Criteria were observational studies in-
cluding adult (age $18 y) populations of any sex or ethnicity, with
a diagnosis of NAFLD and CKD. NAFLD had to be diagnosed by
(1) liver histology, (2) imaging (ultrasound, computer tomography,
magnetic resonance imaging, or spectroscopy), or (3) biochemistry
(elevations in serum AST, ALT, or GGT). Competing causes of
steatosis, including alcohol consumption and viral hepatitis
infection had to be excluded according to standard guidelines
[8]. The presence of CKD had to be defined by (1) persistent (.3
months) GFR,60 ml/min/1.73 m2, as estimated using the
creatinine-based Modified Diet in Renal Disease (MDRD) or
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equations [11,12] or cystatin C–based equation [13], (2) by
creatinine clearance ,60 ml/min per 1.73 m2 using 24-hour
urinary studies, (3) persistent (.3 months) kidney damage
(regardless of GFR), as defined by proteinuria (microalbuminuria
or macroalbuminuria using albumin-to-creatinine ratio, 24-h
albumin excretion rate, or proteinuria on fresh morning urine
dipstick), (4) other abnormalities due to tubular disorders or
NAFLD and CKD
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structural abnormalities detected by electrolyte or urinary
sediment alterations, histology, imaging, or (5) history of kidney
transplantation [2].
Exclusion criteria. Excluded from the meta-analysis were
nnon-human studies, letters/case reports, studies including fewer
than ten individuals, articles not reporting outcomes of interest or
primary data (editorials, reviews), or using inadequate case
definitions. In particular, studies were excluded that did not
adequately consider competing causes of hepatic steatosis includ-
ing alcohol, or viral hepatitis, or that enrolled a mixed population
of cirrhotic and non-cirrhotic individuals (due to the potential
confounding effects of cirrhosis per se on GFR).
Outcome Measures
Primary outcome measures. Primary outcome measures
were differences in the prevalence or incidence of CKD. We
compared the risk of primary outcomes between individuals with
NAFLD and without NAFLD as well as across the main
histological subtypes of NAFLD, since NASH and advanced
fibrosis carry a significantly worse prognosis than steatosis and
milder fibrosis stages, respectively [9]. The impact of NAFLD and
of NAFLD histological subtypes (NASH, advanced fibrosis) on
eGFR, treated as a continuous variable, and on proteinuria, was
also examined.
Secondary outcome measures. The severity of CKD was
the secondary outcome measure. We estimated the effect of the
severity of liver disease in NAFLD, as defined by NASH or
advanced fibrosis, on the stage of CKD. CKD stage was
categorized by GFR according to recent guidelines into CKD
stage 3b (eGFR 30–44 ml/min/1.73 m2, CKD stage 4 (eGFR 15–
29 ml/min/1.73 m2), and CKD stage 5 (eGFR,15 ml/min/
1.73 m2) [2].
Data Extraction and Quality Assessment
Data were extracted from each study independently and in
duplicate by two authors (GM, RG), using a predefined protocol
(supplied in Text S2) and a data extraction sheet based on the
Cochrane Handbook for Systematic Reviews of Intervention [14].
The analysis was carried out in concordance with the Cochrane
Handbook of Systematic Reviews and reported according to
PRISMA guidelines (Text S1) [15]. The initial agreement between
the two reviewers for selection and validity assessment of the
studies was evaluated by the Kappa coefficient. Discrepancies
between the reviewers were resolved by joint discussion and
mutual agreement.
Methodological quality of studies was assessed by the 22-item
STROBE score [16], with two items additionally incorporated
into the checklist. For imaging assessment of NAFLD, examiners
had to be blinded to clinical data, and the exam had to follow pre-
specified, standardized criteria to detect steatosis [17]. For
histological assessment of NAFLD, adequate biopsy specimens
with a fragment length $1.5 cm with more than six portal tracts
had to be obtained and scored by a blinded pathologist according
to standard criteria [8].
Data Synthesis and Analysis
For all included studies, individual participant data (IPD) was
solicited from principal investigators (PIs). PIs were asked to
provide the most complete and updated data, even if the follow-up
was longer than that used for their respective publications. The
quality of the submitted IPD was assessed using pre-specified
methods (see protocol in Text S2), and any inconsistencies were
clarified with the PIs.
Data not available upon database closure, either because the
IPD had not been provided or because full manuscripts had not
been published, were not included in our analyses.
For all analyses, we combined studies providing IPD and studies
providing aggregate data (AD) into a pooled effect measure using
the two-stage method [18,19]: first, the available IPD were
reduced to AD in each study, then these AD (from the IPD studies)
were combined with the existing AD (from the AD studies) using
standard meta-analysis techniques.
In reducing IPD to AD, for dichotomous outcomes we used
multivariate logistic regression in cross-sectional studies to obtain
log odds ratio (OR) with its standard error (SE), and Cox
proportional hazard model in longitudinal studies (all providing
time-to-event data) to obtain log hazard ratio (HR) and its SE
separately for each study. We then combined individual ORs (for
cross-sectional studies) and HRs (for longitudinal studies) and their
95% CIs from all included studies. Associations with continuous
outcome variables were expressed as weighted mean differences
(WMD) with 95% CI. Only the most adjusted risk estimates that
were reported in the studies were included in the analysis. All
measures of dispersion were converted to standard deviations
(SDs).
The study-specific risk estimates were pooled using random-
effects model, because this approach provides a more conservative
assessment of the average effect size than fixed-effects model.
Significance was set at p= 0.05.
The I2 statistic and its 95% CI [20]were calculated to assess
statistical heterogeneity across studies: 0% suggests no heteroge-
neity, 0%–25% very low heterogeneity, 25%–50% low heteroge-
neity, 50%–75% moderate heterogeneity, and a value of .75%
high heterogeneity [14]. In case of I2 values $50%, we explored
individual study characteristics and those of subgroups of the main
body of evidence.
We separately analyzed cross-sectional and longitudinal studies.
Furthermore, for each outcome, the results of studies defining
NAFLD by histology, imaging, or liver enzyme elevation are
presented separately.
Sensitivity analysis was performed by repeating the meta-
analysis after one study at a time was removed to assess whether
any one study significantly affected pooled estimates. Additionally,
a number of subgroup analyses were planned a priori. These
subgroup analyses included repeated analysis after excluding
studies not fulfilling each STROBE item, and separate analyses for
the following items: diabetes: we examined the effect of NAFLD
on CKD in non-diabetic versus diabetic individuals, to assess if the
presence of diabetes affects the association of NAFLD with CKD;
studies simultaneously adjusting versus studies not adjusting for all
the following risk factors for CKD: age, body mass index (BMI),
metabolic syndrome (overall or each of its components), hyper-
tension, smoking status; study design: population-based versus
hospital-based; ethnicity (Asian versus non-Asian population), as
defined by the investigators. As highlighted by the recent report of
the Third Asian Forum of Chronic Kidney Disease Initiatives,
there are striking differences in risk factors for CKD between
Asian ancestry and the remaining ethnicities: as an example,
chronic glomerulonephritis due to IgA nephropathy is among the
three leading causes of CKD in Asians, while it is far less common
in the rest of the world. Different susceptibility loci involved in
innate and adaptive immunity have been identified in recent
genome-wide association studies (GWAS), but also environmental
factors like infections and regular consumption of herbal remedies,
may underlie these epidemiological differences [21–23]. Similarly,
in Asians NAFLD is often encountered in the absence of obesity
and metabolic syndrome and a different genetic background
NAFLD and CKD
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(including different Apolipoprotein C3 gene variants as an
example), has been proposed to account for these ethnic
differences [24].
We therefore explored whether differences in epidemiology of
NAFLD and CKD between Asian and non-Asian populations
affect the association of NAFLD with CKD studies including
exclusively non-cirrhotic patients versus studies including exclu-
sively cirrhotic patients; methods used to estimate GFR; outcomes
related to CKD: studies assessing both eGFR and proteinuria
versus studies assessing solely eGFR or proteinuria; study data
availability: studies providing IPD versus studies providing
exclusively AD.
When eight or more comparisons were available, the effect of
continuous variables including age, whole-body and abdominal
obesity (as estimated by BMI and by waist circumference,
respectively) [25], insulin resistance (estimated by homeostasis
model assessment of insulin resistance [HOMA-IR] index), and
duration of follow-up (for longitudinal studies) on the association
between NAFLD and CKD was evaluated by meta-regression
analysis (random effects model, within-study variance estimated
with the unrestricted maximum-likelihood method).
Small study bias was examined by constructing funnel plots
and by performing the Egger’s test and the trim-and-fill analysis
[26].
Additionally, for the primary end-point we separately per-
formed a one-stage meta-analysis of studies providing IPD, to
examine how the association of NAFLD with CKD was altered
when individual patient level covariates were accounted for
[19,20]. In this analysis, data from all studies providing IPD were
pooled together into a single dataset and effect estimates were
calculated using multivariate logistic regression (cross-sectional
studies) or Cox proportional hazard models (longitudinal studies).
In these models, studies were incorporated as cluster and treated as
random-effect, while covariates were treated as fixed-effect. The
covariates entered in the models were age, BMI, metabolic
syndrome, diabetes, hypertension, smoking status, ethnicity (Asian
versus non-Asian population), presence of cirrhosis, waist circum-
ference, HOMA-index, duration of follow-up (for longitudinal
studies. We first analyzed the influence of each single pre-specified
covariate on the association of NAFLD with CKD with NAFLD
and covariate as fixed-effect and the study as random-effects. In a
second step, we did a complete case multivariable analysis with
respect to NAFLD and all pre-specified covariates.
We used RevMan 5.2 (Nordic Cochrane Center) and SAS 9.2
(SAS Institute) for additional analyses that could not be done with
RevMan. The trim-and-fill analysis was performed with Compre-
hensive Meta-analysis 2.0 (Biostat).
Results
The mean (standard deviation [SD]) agreement between the
two reviewers for study selection and for quality assessment were
0.89 (0.02) and 0.91 (0.04), respectively. The flow of study selection
is reported in Figure 1.
Thirty-three studies (63,902 participants, 16 population-based
and 17 hospital-based, 20 cross-sectional and 13 longitudinal) were
included (Tables 1 and 2) [27–59]. Twenty studies (34,939
participants) were cross-sectional and evaluated the association of
NAFLD with prevalent CKD [27–46]; 13 studies (28,963
participants) were longitudinal (mean duration of follow-up
ranging three to 27 years) and evaluated the association of
NAFLD with new-onset CKD [47–59].
We obtained IPD for 20 studies (61% of included studies,
29,282 participants), including 11 cross-sectional studies (5,145
participants) (Table 1) [27,28,30–35,41–43] and nine longitudinal
studies (24,137 participants) (Table 2) [47–53,55,59].
NAFLD was defined by liver histology in 13 studies (2,205
participants) [27–35,48–51], by ultrasound in 17 studies (35,694
participants) [36–45,52–57], and exclusively by liver enzyme
elevation in three studies (26,003 participants) (Tables 1 and 2)
[46,58,59].
Overall, the methodological quality of the studies was good: the
median (range) STROBE score was 21 (20–22). Three studies did
not report confounder-adjusted estimates and their precision
(STROBE item [p]) [37,45,56], four studies did not discuss their
limitations (item [s]) [30,41,45,58], three studies did not disclose
funding sources and role of the funders (item [v]) [28,44,59], two
studies did not give a cautious overall interpretation of results (item
[t]) [41,58], and one study set the diagnosis of steatosis
retrospectively based on archived images of gallbladder ultrasound
examinations (item [g]) (Tables 1 and 2; Figure S1 within Text S3)
[40].
Twelve studies enrolled exclusively non-diabetic individuals
[28,32,33,35,41,42,45,47,48,52,52,59], four studies enrolled ex-
clusively diabetic patients [36,37,39,54], 11 studies evaluated
diabetic and non-diabetic participants separately [27,30,31,34,
38,43,46,49,50,51,55]. Overall, separate risk estimates for diabetic
and non-diabetic individuals were obtained in 27 studies (82%,
47342 participants).
Twenty-eight studies (85% of all studies, 97% of participants)
adjusted for potential confounders, including all of the following:
age, BMI, metabolic syndrome (overall and each component),
hypertension, and smoking (Tables 1, 2, and 3) [27–29,31–36,38–
41,43,44,46–55,57–59].
Eleven studies enrolled exclusively Asian populations
[31,35,38,41,43,44,45,50,52,53,59], 15 studies enrolled exclusively
non-Asian individuals [27–29,32–34,36,37,39,48,49,54–57], four
studies evaluated separately Asian and non-Asian participants
[27,30,42,47,51]. Overall, separate risk estimates for Asian and
non-Asian individuals were obtained in 30 studies (91%, 36,767
participants).
All studies included non-cirrhotic participants, except one cross-
sectional study comparing NASH-related cirrhosis with cirrhosis of
other aetiologies, matched for Child-Pugh and Model for End-
stage Liver Disease-(MELD) scores [30].
GFR was estimated with the CKD-EPI equation in 16 studies
[27,28,31–34,37,38,41,42,47–51,55] and with the MDRD equa-
tion in 17 studies [29,30,35,36,39,40,43–46,52–54,56,57,59]. One
study assessed only proteinuria and not eGFR [58], while seven
studies (21%) evaluated only eGFR and not proteinuria [27,30,
34,42,48,49,56].
NAFLD and Prevalent/Incident CKD
In cross-sectional studies, pooled OR for the presence of CKD
of NAFLD versus non-NAFLD was 2.12 (95% CI 1.69–2.66,
I2 = 77% [95% CI 66%–84%], N-comparisons = 17, p,0.00001)
(Figure 2). The magnitude and direction of the effect were similar
across different NAFLD definitions (Figure 2). Heterogeneity was
high, due to the high heterogeneity in studies assessing NAFLD by
ultrasound, but fell after excluding one study [40], where the
diagnosis of steatosis was made retrospectively on the basis of
archived videotapes of gallbladder ultrasound examinations, while
pooled OR remained similar in magnitude and direction of the
overall effect (OR 2.11, 95% CI 1.82–2.44; I2 = 29% [95% CI
15%–35%], n= 16, p,0.00001) (Table 3).
In longitudinal studies, pooled HR for incident CKD of
NAFLD versus non-NAFLD was 1.79 (95% CI 1.65–1.95,
I2 = 0% [95% CI 0%–18%], n comparisons = 13, p,0.00001)
NAFLD and CKD
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Figure 1. Flow of study selection. STROBE score of included studies is provided as median (range).
doi:10.1371/journal.pmed.1001680.g001
NAFLD and CKD
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(Figure 3). There was no heterogeneity in the meta-analysis of
overall events, suggesting a consistent disease effect.
In both cross-sectional and longitudinal studies, the difference
between NAFLD and non-NAFLD patients remained statistically
significant even when considering eGFR as a continuous variable
or when considering only proteinuria as outcome (Figures S2A,
S2B, S3A, and S3B within Text S3).
In both cross-sectional and longitudinal studies, meta-regression
analysis found no association between CKD and age (cross-
sectional studies: b= 0.004, 95% CI 20.023 to 0.031, p = 0.772;
longitudinal studies: b= 0.005, 95% CI 20.014 to 0.021,
p = 0.207), BMI (cross-sectional studies: b= 0.013, 95% CI
20.034 to 0.059, p= 0.592; longitudinal studies: b= 0.003, 95%
CI 20.019 to 0.026, p= 0.786), waist circumference (cross-
sectional studies: b=20.003, 95% CI 20.023 to 0.031,
p = 0.772; longitudinal studies: b=20.003, 95% CI 20.016 to
0.011, p= 0.686), HOMA-IR index (cross-sectional studies:
b= 0.089, 95% CI 20.210 to 0.388, p = 0.559; longitudinal
studies: b=20.041, 95% CI 20.171 to 0.087, p = 0.524), and
duration of follow-up (longitudinal studies: b= 0.002, 95% CI
20.022 to 0.026, p= 0.880).
The Egger’s test found no strong evidence for small study bias
and the trim-and-fill analysis did not appreciably attenuate the
strength of the association (Figures S4A and S4B within Text S3).
NAFLD Histological Subtypes and the Risk of CKD in
Non-cirrhotic NAFLD
Cross-sectional studies. In cross-sectional studies, pooled
OR for CKD of NASH versus steatosis was 2.53 (95% CI 1.58–
4.05, I2 = 0% [95% CI 0%–14%], n-comparisons = 8, p= 0.0001)
(Figure 4). Pooled OR for CKD of advanced (stage F3) versus non-
advanced (stage F0–F2) fibrosis was 5.20 (95% CI 3.14–8.61,
I2 = 0% [95% CI 0%–17%], n = 9, p,0.00001) (Figure 4). There
was no heterogeneity in the meta-analyses of overall events,
suggesting a consistent disease effect.
NASH and advanced fibrosis were also associated with higher
ORs for proteinuria and with a lower eGFR than steatosis and
non-advanced fibrosis, respectively (Figures S5A, S5B, S6A, and
S6B within Text S3).
Meta-regression analysis found no association between CKD
and age (for NASH: b= 0.050, 95% CI 20.039 to 0.140,
p = 0.269; for advanced fibrosis: b= 0.002, 95% CI 20.101 to
0.105, p = 0.964), BMI (for NASH: b= 0.003, 95% CI 20.049 to
0.056, p = 0.896; for advanced fibrosis: b= 0.002, 95% CI 20.007
to 0.065, p= 0.949), waist circumference (for NASH: b= 0.004,
95% CI 20.031 to 0.040, p = 0.812; for advanced fibrosis: b=
20.004, 95% CI 20.043 to 0.034, p = 0.820), and HOMA-IR
index (for NASH: b=20.231, 95% CI 20.691 to 0.229,
p = 0.324; for advanced fibrosis: b=20.161, 95% CI 20.705 to
0.383, p = 0.562).
The Egger’s test found no strong evidence for small study bias
and the trim-and-fill analysis did not appreciably attenuate the
strength of the association (Figures S4A–S4D within Text S3).
Longitudinal studies. In longitudinal studies, pooled HR for
incident CKD of NASH versus simple steatosis was 2.12 (95% CI
1.42–3.17, I2 = 0% [95% CI 0%–19%, n-comparisons = 7,
p = 0.0002) (Figure 5). Pooled HR for CKD of advanced fibrosis
versus non-advanced fibrosis was 3.29 (95% CI 2.30–4.71, I2 = 0%
[95% CI 0%–18%], n = 7, p,0.00001) (Figure 5). There was no
heterogeneity in the meta-analyses of overall events, again
suggesting a consistent disease effect.
NASH and advanced fibrosis were also associated with a higher
OR for incident proteinuria and with more severe eGFR
reduction than steatosis and non-advanced fibrosis, respectively
(Figures S7A, S7B, S8A, and S8B within Text S3).
Meta-regression analysis found no association between CKD
and age (for NASH: b=20.019, 95% CI 20.113 to 0.774,
p = 0.681; for advanced fibrosis: b=20.007, 95% CI 20.088 to
0.074, p= 0.868), BMI (for NASH: b=20.106, 95% CI 20.366
to 0.154, p= 0.425; for advanced fibrosis: b=20.075, 95% CI
20.307 to 0.158, p = 0.529), waist circumference (for NASH:
b=20.026, 95% CI 20.116 to 0.060, p= 0.559; for advanced
fibrosis: b=20.026, 95% CI 20.101 to 0.050, p= 0.508),
HOMA-IR index (for NASH: b= 0.167, 95% CI 20.153 to
0.487, p = 0.306; for advanced fibrosis: b= 0.048, 95% CI 20.376
to 0.472, p = 0.825) and duration of follow-up (for NASH: b=
20.012, 95% CI 20.067 to 0.043, p = 0.675; for advanced
fibrosis: b=20.006, 95% CI 20.058 to 0.046, p = 0.817).
The Egger’s test found no strong evidence for small study bias
and the trim-and-fill analysis did not appreciably attenuate the
strength of the association (Figures S4E and S4F within Text S3).
NAFLD Histological Subtypes and the Stage of CKD in
Non-cirrhotic NAFLD
Cross-sectional studies. In cross-sectional studies, pooled
OR for CKD stage 3b of NASH versus steatosis was 3.38 (95% CI
1.11–10.31, I2 = 0% [95% CI 0%–17%], n-comparisons = 8,
p= 0.03) (Figure S9A within Text S3). Pooled OR for CKD stage
3b of advanced versus non-advanced fibrosis was 26.98 (95% CI
9.12–79.84, I2 = 0% [95% CI 0%–21%], n= 9 p,0.00001) (Figure
S9B within Text S3). There was no heterogeneity in the meta-
analysis of overall events, suggesting a consistent disease effect.
The presence of serum creatinine elevation, configuring severely
decreased renal function (CKD stage 4) or renal failure (CKD stage 5),
was an exclusion criterion in cross-sectional studies, which focused on
the association of NAFLD with clinically unrecognized (stage 1–3) CKD.
Longitudinal studies. In longitudinal studies, pooled HR for
CKD stage 3b, 4, and 5 (renal failure) was significantly higher in
NASH versus steatosis: OR for CKD stage 3b: 2.49 (95% CI
1.21–5.13, I2 = 0% [95% CI 0%–21%], n-comparisons = 7,
p = 0.01); OR for CKD stage 4: 3.45 (95% CI 1.15–10.39,
I2 = 0% [95% CI 0%–18%], n-comparisons = 6, p= 0.03); OR for
CKD stage 5: 3.87 (95% CI 1.10–13.58, I2 = 0% [95% CI 0%–
16%], n-comparisons = 6, p= 0.03) (Figures 6 and 7).
Similarly, pooled HR for CKD stage 3b, 4, and 5 (renal failure)
was significantly higher in advanced versus non-advanced fibrosis:
OR for CKD stage 3b: 7.48 (95% CI 2.95–18.97, I2 = 23% [95%
CI 0%–35%], n-comparisons = 7, p,0.0001); OR for CKD stage
4: 7.66 (95% CI 2.72–21.56, I2 = 0% [95% CI 0%–16%], n-
comparisons = 6, p= 0.0001); OR for CKD stage 5: 12.67 (95%
CI 4.49–35.76, I2 = 0% [95% CI 0%–26%], n-comparisons = 6,
p,0.00001) (Figures 7 and 8).
There was no heterogeneity in the meta-analysis of overall
events, suggesting a consistent disease effect.
Subgroup Analyses
NAFLD and prevalent/incident CKD. The magnitude and
direction of the associations were unaltered across studies
fulfilling different STROBE score items in non-diabetic individ-
uals (Figures S10–S14 and S23–S26 within Text S3) versus
diabetic individuals (Figures S15 and S27 within Text S3), when
the analysis was restricted to studies adjusting for age and BMI
and metabolic syndrome and hypertension and smoking status
(Figures S16 and S28 within Text S3), in population-based versus
hospital-based studies (Figures S17 and S29 within Text S3), in
studies including Asian versus non-Asian individuals (Figures S18
and S30 within Text S3), in studies using CKD-EPI versus
NAFLD and CKD
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studies using the MDRD equation (Figures S20 and S31 within
Text S3), after exclusion of studies assessing only eGFR or
proteinuria (Figures S21 and S32 within Text S3), and in studies
providing IPD versus studies providing exclusively AD (Figures
S22 and S33 within Text S3). Furthermore, the main results
remained largely unaltered after excluding the only cross-
sectional study including cirrhotic individuals (Figure S19 within
Text S3), while no prospective study enrolled subjects with
cirrhosis at baseline. Subgroup analyses are summarized in
Table 3.
NAFLD Histological Subtypes and the Risk of CKD
NASH/advanced fibrosis and prevalent CKD. The mag-
nitude and direction of the effect were unaltered across studies
fulfilling different STROBE score items (Figures S34 and S38
within Text S3) in non-diabetic versus diabetic individuals (Figures
S35 and S39 within Text S3), in studies including Asian versus
non-Asian individuals (Figures S36 and S40 within Text S3), in
studies using CKD-EPI versus studies using the MDRD equation
(Figure S41 within Text S3), after exclusion of studies assessing
only eGFR or proteinuria (Figures S37 and S42 within Text S3),
and in studies providing IPD versus studies providing exclusively
AD (Figure S43 within Text S3).
All studies adjusted for traditional risk factors for CKD, were
hospital-based and enrolled non-cirrhotic patients.
NASH/advanced fibrosis and incident CKD. The magni-
tude and direction of the effect remained unaltered in non-diabetic
versus diabetic individuals (Figures S44 and S47 within Text S3),
in Asian versus non-Asian individuals (Figures S45 and S48 within
Text S3) and after exclusion of studies assessing only eGFR
(Figures S46 and S49 within Text S3). All studies satisfied all
STROBE score items, were hospital-based, enrolled non-cirrhotic
individuals, adjusted for traditional risk factors for CKD, and used
CKD-EPI equation to estimate GFR.
One-Stage Individual Participant Data Meta-analysis
Twenty studies (29,282 participants, 11 cross-sectional studies,
nine longitudinal studies) were included in this analysis. We first
analyzed the influence of each single pre-specified individual
patient level covariate on the association of NAFLD with CKD with
NAFLD and covariate as fixed-effect and the study as random-
effects. In a second step, we did a complete case multivariable
analysis with respect to NAFLD and all pre-specified covariates. The
covariates entered in the models were age, BMI, metabolic syndrome
(presence versus absence), diabetes (presence versus absence),
hypertension (presence versus absence), smoking status (current
smokers versus non-smokers), ethnicity (Asian versus non-Asian
population), cirrhosis (presence versus absence), waist circumference,
HOMA-index, duration of follow-up (for longitudinal studies).
The magnitude of the effect of NAFLD on CKD remained
largely unaffected after adjusting for the covariates separately and
in the fully adjusted models (Table 4).
Discussion
The main results of our analysis are the following: (1) NAFLD
was associated with an increased prevalence and incidence of
CKD; (2) liver disease severity in NAFLD was associated with an
increased risk and severity of CKD; (3) these associations remained
statistically significant in diabetic and non-diabetic individuals, as
well as in studies adjusting for traditional risk factors for CKD, and
were independent of whole body/abdominal obesity and insulin
resistance.T
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The prevalence of CKD is rapidly growing and in the United
States over 1.1 million individuals are estimated to have ESRD by
the year 2015 [60]. In addition to progressing to ESRD, CKD is
also a major risk factor for CVD, and most individuals with CKD
die from CVD before they develop ESRD. Therefore, the search
for modifiable risk factors for CKD is attracting much attention.
NAFLD is an emerging risk factor for end-stage liver disease
and CVD: the frequency of NASH as the primary indication for
liver transplantation has increased from 1.2% to 9.7% in the last
decade, becoming the third most common indication for liver
transplantation in the United States [61]. Furthermore, the
number of combined liver and kidney transplants has been
increasing exponentially in the last 5 years [62], thereby
challenging cost-effective resource utilization in the treatment of
end-stage organ disease. For these reasons, establishing a link
between liver and kidney injury would enhance earlier identification
of kidney disease and allow for the selection of treatments targeting
both liver disease and CKD progression in individuals with
NAFLD, with potentially relevant preventive and therapeutic
implications. Our analysis disclosed an association between the
presence and severity of NAFLD and the risk and severity of CKD.
This association remained robust in cross-sectional and longitudinal
studies, across different definitions (imaging, histology, biochemistry)
of NAFLD and after taking different confounders into account.
Notably, heterogeneity across cross-sectional studies evaluating
NAFLD by ultrasound was abated after excluding data from analysis
of the NHANES III 1988–1994 cohort, which failed to find an
association between NAFLD and CKD [40]. This finding may be at
least partially explained by the protocol used in that study: NHANES
III was not originally designed to study hepatic steatosis and the
authors diagnosed NAFLD retrospectively, on the basis of archived
videotapes of gallbladder ultrasound examinations. In 2009–2010,
trained ultrasound readers examined the protocol used in that study
and found only modest intra- and inter-reliability for the presence of
hepatic steatosis, i.e., 0.77 (95% CI 0.73–0.82) and 0.70 (95% CI
0.64–0.76), respectively [63–65]. This flaw may have further diluted
Figure 2. Forest plot of comparison. NAFLD versus non-NAFLD, outcome: prevalent chronic kidney disease in cross-sectional studies. Studies
assessing NAFLD by imaging, histology or liver enzyme elevation were considered separately.
doi:10.1371/journal.pmed.1001680.g002
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the disease effect on CKD through misclassification of NAFLD cases
as non-NAFLD, since mild steatosis, often present in progressive
NASH and advanced fibrosis, is frequently missed by ultrasound.
Implications for Practice
Current guidelines do not recommend screening for CKD in
the absence of traditional risk factors for CKD [66]. Our data
suggest that individuals with NAFLD should be screened for CKD
by estimation of GFR and urinalysis even in the absence of
classical risk factors for CKD, particularly if NASH and/or
advanced fibrosis are suspected. Early recognition of impaired
kidney function in NAFLD may also allow drug dosage
adjustment, thus preventing drug accumulation, especially in
those being treated for obesity-associated comorbidities.
Figure 3. Forest plot of comparison. NAFLD versus non-NAFLD, outcome: incident chronic kidney disease in prospective studies. NAFLD was
defined by imaging, histology, or liver enzyme elevation. Studies assessing NAFLD by imaging, histology, or liver enzyme elevation were considered
separately.
doi:10.1371/journal.pmed.1001680.g003
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From a therapeutic standpoint, there is a considerable potential
for improving the current care of NAFLD patients with CKD:
with respect to lifestyle interventions, smoking cessation should be
more vigorously pursued, as cigarette smoking is an established
risk factor for CKD, and may also aggravate NAFLD [67,68].
Among pharmacological options, preliminary data from the
GREACE and FANTASY randomized trials suggest statins and
angiotensin receptor blockers (ARBs) may improve both liver and
kidney disease in NAFLD [56,69–71]. Beside statins and ARBs,
other agents, including pentoxifylline and v-3 polyunsaturated
fatty acids, improved surrogate markers of NAFLD and CKD in
distinct NALFD-associated settings like obesity, diabetes, and
hypertension, and their impact on CKD in NAFLD warrants
future assessment [72–76].
Figure 4. Forest plot of comparison. (A) NASH versus simple steatosis in biopsy-proven non-cirrhotic NAFLD; outcome: prevalent chronic kidney
disease in cross-sectional studies. (B) Advanced (stage F3) fibrosis versus no-advanced (stage F0–F2) fibrosis in biopsy-proven non-cirrhotic NAFLD,
outcome: prevalent CKD in cross-sectional studies.
doi:10.1371/journal.pmed.1001680.g004
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Implications for Research
Further research is required to unravel the specific cascades
linking NAFLD and kidney disease. NAFLD and CKD share
common risk factors and therefore both liver and kidney injury
may be driven by obesity-associated mechanisms of disease,
including lipotoxicity, oxidative stress, enhanced pro-inflammatory
cytokine, and renin-angiotensin-aldosterone system (RAAS) axis
activation [10,77–80]. However, our analysis of longitudinal
studies suggests NAFLD may promote CKD independently of
coexisting risk factors. Consistently, recent data suggest the
steatotic and inflamed liver may be a relevant source of pro-
inflammatory, pro-fibrogenic, and anti-fibrinolytic molecules,
including fetuin-A, fibroblast growth factor (FGF)-21, tumor
necrosis factor (TNF)-a, transforming growth factor (TGF)-b,
Figure 5. Forest plot of comparison. (A) NASH versus simple steatosis in biopsy-proven noncirrhotic NAFLD; outcome: incident CKD in
prospective studies. (B) Advanced (stage F3) fibrosis versus no-advanced (stage F0–F2) fibrosis in biopsy-proven non-cirrhotic NAFLD, outcome:
incident CKD in prospective studies.
doi:10.1371/journal.pmed.1001680.g005
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and plasminogen activator inhibitor-1, all having the ability to
promote kidney injury [81–85]. Furthermore, fatty liver may
damage the kidney through VLDL lipoprotein over-secretion and
induction of atherogenic dyslipidemia [86,87], as triglyceride-rich
lipoproteins and oxidized LDLs promote glomerular injury and
mesangial cell proliferation [77].
We also found a cross-sectional association between NAFLD
and CKD, implying that even mild renal dysfunction may
promote liver disease, in a mutual negative loop with detrimental
cardio-metabolic consequences Consistently, uni-nephrectomized
rats developed body fat redistribution from adipose depots to non-
adipose tissues, profound dysregulation of hepatic fatty acid
metabolism, steatohepatitis, insulin resistance, hyperglycaemia,
and dyslipidaemia early after uni-nephrectomy and long
before glomerulosclerosis and chronic renal failure occur
[88,89]. Notably, all renal and metabolic changes were prevented
Figure 6. Forest plot of comparison. (A) NASH versus simple steatosis in biopsy-proven non-cirrhotic NAFLD; outcome: incident CKD stage 3b in
prospective studies. (B) NASH versus simple steatosis in biopsy-proven non-cirrhotic NAFLD; outcome: incident CKD stage 4 in prospective studies.
doi:10.1371/journal.pmed.1001680.g006
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by angiotensin converting enzyme (ACE) inhibitors in
this experimental model, indicating the involvement of the RAAS
[74].
Lastly, since NAFLD is an emerging risk factor for liver-related
and cardiovascular complications, the hypothesis that the presence
of CKD may represent a simple, cost-effective tool to predict
increased liver-related and CVD risk in NAFLD is intriguing and
warrants assessment in large-scale prospective studies. Currently,
in fact, there is no validated non-invasive marker to predict the risk
of both liver disease progression and future CVD, the main causes
of death in NAFLD patients [9].
Our findings may also have therapeutic research implications.
Future trials will need to evaluate the impact of experimental
treatments on kidney-related outcomes. Notably, only two of the
available randomized controlled trials in NAFLD reports the effect
of drugs on eGFR and proteinuria and none has adequate size and
Figure 7. Forest plot of comparison. (A) NASH versus simple steatosis in biopsy-proven non-cirrhotic NAFLD; outcome: incident CKD stage 5
(renal failure) in prospective studies. (B) Advanced (stage F3) fibrosis versus no advanced (stage F0–F2) fibrosis in biopsy-proven non-cirrhotic NAFLD;
outcome: incident CKD stage 3b in prospective studies.
doi:10.1371/journal.pmed.1001680.g007
NAFLD and CKD
PLOS Medicine | www.plosmedicine.org 20 July 2014 | Volume 11 | Issue 7 | e1001680
duration to evaluate the impact of treatments on kidney-related
clinical outcomes.
Our analysis has limitations, which are intrinsic to the nature of
included studies and provide the basis for future research. Studies
with biopsy-proven NAFLD were by their own nature less
numerous and smaller than those adopting ultrasonographic/
biochemical definitions of NAFLD, leaving the possibility of small
study bias that is not detected by current tests. Furthermore, these
studies were performed in tertiary centers with the possibility of
selection bias. Conversely, ultrasound/liver enzyme elevations are
relatively insensitive to detect NAFLD, with possible misclassifi-
cation of individuals with NASH/advanced fibrosis as healthy
controls and underestimation of the strength of the association
between NAFLD and CKD. However, there was no heterogeneity
between studies: disease effect on CKD.
Finally, despite our best efforts IPD were unavailable from
as much as 39% of relevant studies, representing 54% of
participant population. While meta-analysis of AD has several
Figure 8. Forest plot of comparison. (A) advanced (stage F3) fibrosis versus no advanced (stage F0–F2) fibrosis in biopsy-proven non-cirrhotic
NAFLD; outcome: incident CKD stage 4 in prospective studies. (B) Advanced (stage F3) fibrosis versus no advanced (stage F0–F2) fibrosis in biopsy-
proven non-cirrhotic NAFLD; outcome: incident (CKD) stage 5 (renal failure) in prospective studies.
doi:10.1371/journal.pmed.1001680.g008
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limitations, including ecological bias and study-level confound-
ing, excluding such a substantial proportion of relevant
literature from our analysis would have raised the concern of
data availability bias [90]. Furthermore, the methodological
quality of the 13 studies providing exclusive AD was generally
good, 77% of them adjusted for all potential confounders,
and 69% of them allowed separate risk estimates for
individual patient level covariates (including diabetes, cirrho-
sis, ethnicity).
Balancing all these reasons, we presented all relevant literature
evidence by combining IPD with AD in the main analysis, and
separately analyzed studies providing IPD with a one-stage
method: notably, the two analyses yielded similar results, further
supporting the robustness of overall findings.
In conclusion, our analysis shows that the presence
and severity of NAFLD are associated with an increased risk
and severity of CKD and may be a target for the prevention and
treatment of CKD. Future research should evaluate strategies and
interventions to prevent renal disease progression in individuals
with NAFLD.
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FB SH ESB MA LH XG SF AV YY KDL MC RH HV MML RR SR GL
LLW MM HCP KY MC. Enrolled patients: GM RG JHT ME SK MH
RH HH SKY PC JG FB SH ESB MA LH XG SF AV YY KDL MC RH
HV MML RR SR GL LLW MM HCP KY MC.
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Editors’ Summary
Background. Chronic kidney disease (CKD)—the gradual
loss of kidney function—is becoming increasingly common.
In the US, for example, more than 10% of the adult
population (about 26 million people) and more than 25%
of individuals older than 65 years have CKD. Throughout life,
the kidneys perform the essential task of filtering waste
products (from the normal breakdown of tissues and from
food) and excess water from the blood to make urine. CKD
gradually destroys the kidneys’ filtration units, the rate of
blood filtration decreases, and dangerous amounts of waste
products build up in the blood. Symptoms of CKD, which
rarely occur until the disease is very advanced, include
tiredness, swollen feet, and frequent urination, particularly at
night. There is no cure for CKD, but progression of the
disease can be slowed by controlling high blood pressure
and diabetes (two risk factors for CKD), and by adopting a
healthy lifestyle. The same interventions also reduce the
chances of CKD developing in the first place.
Why Was This Study Done? CKD is associated with an
increased risk of end-stage renal (kidney) disease and of
cardiovascular disease. These life-threatening complications
are potentially preventable through early identification and
treatment of CKD. Because early recognition of CKD has the
potential to reduce its health-related burden, the search is
on for new modifiable risk factors for CKD. One possible new
risk factor is non-alcoholic fatty liver disease (NAFLD), which,
like CKD is becoming increasingly common. Healthy livers
contain little or no fat but, in the US, 30% of the general
adult population and up to 70% of patients who are obese or
have diabetes have some degree of NAFLD, which ranges in
severity from simple fatty liver (steatosis), through non-
alcoholic steatohepatitis (NASH), to NASH with fibrosis
(scarring of the liver) and finally cirrhosis (extensive scarring).
In this systematic review and meta-analysis, the researchers
investigate whether NAFLD is a risk factor for CKD by looking
for an association between the two conditions. A systematic
review identifies all the research on a given topic using
predefined criteria, meta-analysis uses statistical methods to
combine the results of several studies.
What Did the Researchers Do and Find? The researchers
identified 33 studies that assessed NAFLD and CKD in nearly
64,000 participants, including 20 cross-sectional studies in
which participants were assessed for NAFLD and CKD at a
single time point and 13 longitudinal studies in which
participants were assessed for NAFLD and then followed up
to see whether they subsequently developed CKD. Meta-
analysis of the data from the cross-sectional studies indicated
that NAFLD was associated with a 2-fold increased risk of
prevalent (pre-existing) CKD (an odds ratio [OR]of 2.12; an OR
indicates the chance that an outcome will occur given a
particular exposure, compared to the chance of the outcome
occurring in the absence of that exposure). Meta-analysis of
data from the longitudinal studies indicated that NAFLD was
associated with a nearly 2-fold increased risk of incident (new)
CKD (a hazard ratio [HR] of 1.79; an HR indicates often a
particular event happens in one group compared to how
often it happens in another group, over time). NASH was
associated with a higher prevalence and incidence of CKD
than simple steatosis. Similarly, advanced fibrosis was associ-
ated with a higher prevalence and incidence of CKD than non-
advanced fibrosis.
What Do These Findings Mean? These findings suggest
that NAFLD is associated with an increased prevalence and
incidence of CKD and that increased severity of liver disease
is associated with an increased risk and severity of CKD.
Because these associations persist after allowing for estab-
lished risk factors for CKD, these findings identify NAFLD as
an independent CKD risk factor. Certain aspects of the
studies included in this meta-analysis (for example, only a
few studies used biopsies to diagnose NAFLD; most used less
sensitive tests that may have misclassified some individuals
with NAFLD as normal) and the methods used in the meta-
analysis may limit the accuracy of these findings. Neverthe-
less, these findings suggest that individuals with NAFLD
should be screened for CKD even in the absence of other risk
factors for the disease, and that better treatment of NAFLD
may help to prevent CKD.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001680.
N The US National Kidney and Urologic Diseases Information
Clearinghouse provides information about all aspects of
kidney disease; the US National Digestive Diseases
Information Clearinghouse provides information about
non-alcoholic liver disease
N The US National Kidney Disease Education Program
provides resources to help improve the understanding,
detection, and management of kidney disease (in English
and Spanish)
N The UK National Health Service Choices website provides
information for patients on chronic kidney disease,
including some personal stories, and information on non-
alcoholic fatty liver disease
N The US National Kidney Foundation, a not-for-profit
organization, provides information about chronic kidney
disease (in English and Spanish)
N The not-for-profit UK National Kidney Federation provides
support and information for patients with kidney disease
and for their carers
N The British Liver Trust, a not-for-profit organization,
provides information about non-alcoholic fatty liver
disease, including a patient story
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